Results 1 to 10 of about 585,966 (213)

Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma. [PDF]

Blood Adv
: This real-world retrospective cohort study evaluated utilization and comparative effectiveness of covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapies in relapsed/refractory mantle cell lymphoma (R/R MCL) from electronic health records in ...
Phillips T, Di M, Miller TA, Wang J, Pierre A, Maglinte GA, Seymour EK, Wang Y.   +7 more
europepmc   +2 more sources

Ibrutinib inhibits the replication of multiple poxviruses by targeting the Bruton tyrosine kinase. [PDF]

J Virol
The recent surge in global monkeypox (mpox) outbreaks highlights the critical need for developing antiviral agents targeting orthopoxvirus infections. Ibrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor initially approved by the FDA in 2013 for
Niu K, Wang X, Jiang Q, Liu K, Xie S, Song B, Wu W, Li X, Li X, Peng C.   +9 more
europepmc   +2 more sources

The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT

Efficacy and Mechanism Evaluation
Background Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase ...
Cook JA, Patten P, Peckham N, Moss P, Abhishek A, Barber VS, Francis A, Duley L, Hoogeboom R, Willett BJ, Vandici G, Plested G, Eldridge L, Julier P, Roberts T, Hodges M, Parry HM.   +16 more
europepmc   +2 more sources

Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Frontiers in Oncology, 2021
Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis.
Ting-Ting Yang, Ting-Ting Yang, Ting-Ting Yang, Wei-Hao Chen, Wei-Hao Chen, Wei-Hao Chen, Yan-Min Zhao, Yan-Min Zhao, Yan-Min Zhao, Hua-Rui Fu, Hua-Rui Fu, Hua-Rui Fu, He Huang, He Huang, He Huang, Ji-Min Shi, Ji-Min Shi, Ji-Min Shi   +17 more
doaj   +1 more source

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases

Frontiers in Oncology, 2021
Vitreoretinal lymphoma (VRL) is a rare intraocular malignancy, and standard treatment approaches have not been defined yet. Bruton tyrosine kinase inhibitors are found to be effective in the treatment of primary central nervous system diffuse large B ...
Liang Wang, Wenxue Guan, Xiaoyan Peng
doaj   +1 more source

Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome

Frontiers in Immunology, 2022
Schnitzler syndrome is a rare adult-onset acquired autoinflammatory disorder typically characterized by chronic urticarial rash and immunoglobulin M (IgM) (rarely IgG) monoclonal gammopathy.
Yuehua Huang, Yanying Wang, Fan Yu, Xuehan Mao, Bianhong Wang, Jingxian Li, Lihong Li   +6 more
doaj   +1 more source

Bing–Neel Syndrome: Update on Diagnosis and Treatment

Hemato, 2022
Bing–Neel syndrome (BNS) is a rare neurological complication of Waldenström macroglobulinaemia. We highlight key issues in clinical presentation, diagnosis, and treatment while focusing on new and emerging therapies available for patients diagnosed with ...
Evangeline Y. Wong, Shirley D’Sa, Monique C. Minnema, Jorge J. Castillo, Dipti Talaulikar   +4 more
doaj   +1 more source

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK

eJHaem, 2021
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute for Health and Care Excellence in January 2017, represented a
Peter Hillmen, Jing Xie, Alan S. M. Yong, Catherine Waweru, Thuy Anh Sorof, Ravi K. Goyal, Keith L. Davis   +6 more
doaj   +1 more source

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

Metabolism Open, 2021
Coronavirus disease 2019 (COVID-19) is first detected in December 2019 in Wuhan, China which is a new pandemic caused by SARS-COV-2 that has greatly affected the whole world.
Zemene Demelash Kifle
doaj   +1 more source

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

Haematologica, 2018
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson, Craig E. Hughes, Stephanie Watson, Sophie H. Nock, Alexander T. Hardy, Callum N. Watson, Samantha J. Montague, Hayley Clifford, Aarnoud P. Huissoon, Jean-Daniel Malcor, Mark R. Thomas, Alice Y. Pollitt, Michael G. Tomlinson, Guy Pratt, Steve P. Watson   +14 more
doaj   +1 more source